Recent share performance and business profile

Pulse Biosciences (PLSE) has drawn attention after a strong share price move over the past 3 years, even as returns over the past month have been weaker and the stock remains volatile in the shorter term.

The company, valued at about US$1.42b, focuses on bioelectric medicine, with products built around its nPulse Nanosecond Pulsed Field Ablation platform. These systems target benign skin lesions and soft tissue ablation, including tools designed for cardiac procedures such as atrial fibrillation.

Despite reporting revenue of US$0.35m from surgical and medical equipment, Pulse Biosciences recorded a net loss of US$72.78m in the latest annual figures provided. That gap between revenue and net income is an important starting point for anyone looking at the stock primarily as a growth stage medical technology play.

The recent share price pullback, with a 7 day share price return of a 9.51% decline and a 30 day share price return of a 9.43% decline, comes after stronger momentum, including a 90 day share price return of 51.93% and a 3 year total shareholder return of 176.44%. This suggests recent enthusiasm has cooled, even though longer term holders still see sizeable gains on paper.

If you are weighing Pulse Biosciences against other medical and AI focused names, this could be a useful moment to scan for 33 healthcare AI stocks and see how they compare on risk and reward.

With a share price of US$20.83, a market value of about US$1.42b, limited revenue of US$0.35m and a US$30 analyst target, is Pulse Biosciences mispriced, or is the market already banking on years of future growth?

Most Popular Narrative: 5.3% Undervalued

At a last close of US$20.83 against a narrative fair value of US$22, the current price sits slightly below what this widely followed view suggests, and the gap turns on a very specific growth and margin story.

Early commercial traction of the nPulse Vybrance system in benign thyroid nodule ablation, supported by growing procedure volumes and positive physician feedback, positions the company to convert existing thyroidectomy volume and unlock a large base of watchful waiting patients, which should accelerate revenue growth and increase recurring disposable sales.

Curious what underpins that fair value call? The narrative leans heavily on rapid revenue expansion, a major margin reset, and a future earnings multiple that most investors would not expect at first glance.

Result: Fair Value of $22 (UNDERVALUED)

However, this hinges on clinical and reimbursement progress. Slow adoption or prolonged losses could quickly challenge the idea that the shares are modestly undervalued.

Another view: valuation gap using book value

The fair value narrative points to mild undervaluation, but the picture shifts when you look at book value. Pulse Biosciences trades on a P/B of 17.6x versus 3.4x for peers and 2.3x for the wider US Medical Equipment group, with no fair ratio available to suggest where that multiple could settle. For a company with US$350K of revenue and ongoing losses, that premium raises a simple question: how comfortable are you paying this much above the sector for a still early stage story?

Next Steps

With sentiment clearly mixed, and both risk and reward on the table, it makes sense to review the numbers yourself and move quickly to form your own stance by weighing the 1 key reward and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on opportunities that might suit your style and goals even better, so broaden your search with a few focused screens.

• Target potential value plays by scanning 50 high quality undervalued stocks that pair solid fundamentals with room for the market to reassess their pricing.
• Prioritise resilience by checking solid balance sheet and fundamentals stocks screener (44 results) that can better handle tough conditions while still offering meaningful growth potential.
• Get ahead of the crowd by reviewing a screener containing 25 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.